INTELLIGENT BIO SOLUTIONS INC.
No SEC Form 4 filings for $INBS in the last 30 days.
See all $INBS insider activity →Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
Intelligent Bio Solutions (INBS) said it completed precision testing for its Intelligent Fingerprinting Drug Screening System for an FDA 510(k) submission. The company reported reproducible results across 1,600+ tests, three production runs, and three independent sites. The data will be included with other study results in the application, supporting a planned U.S. launch after clearance. INBS stock closed at $1.81, down 8.12%.
Intelligent Bio Solutions (INBS) announced it has regained compliance with Nasdaq's minimum bid price requirement as of January 7, 2026. This follows its common stock trading below $1.00 for 30 consecutive business days, leading to a deficiency notice in December 2025. The company maintained a closing bid price of at least $1.00 for 14 consecutive business days, removing the immediate delisting risk.
Over the past 7 days, alphai's AI scored 1 news story mentioning INBS (INTELLIGENT BIO SOLUTIONS INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent INBS coverage spans financial news, market movers and regulation.
Improves regulatory readiness for FDA clearance efforts, which can be a key gating item for commercialization.
Completion of precision testing is a procedural FDA step that can de-risk the 510(k) package, but it does not confirm clearance or timing.
Intelligent Bio Solutions (INBS) has regained Nasdaq listing compliance, reducing delisting risk and potentially restoring investor confidence.
The partnership between Intelligent Bio Solutions (INBS) and Syrma Johari MedTech is a positive development, indicating potential growth in production capacity and cost savings. This could lead to improved financial performance and increased investor confidence.
The announcement of a manufacturing partnership by INBS to reduce costs and expand capacity is likely to positively influence the company's stock performance in the near term.
alphai scores every news story that mentions INBS with an AI model for sentiment and relevance, and aggregates insider trades from INTELLIGENT BIO SOLUTIONS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
7 min readIntelligent Bio Solutions (INBS) said it completed precision testing for its Intelligent Fingerprinting Drug Screening System for an FDA 510(k) submission. The company reported reproducible results across 1,600+ tests, three production runs, and three independent sites. The data will be included with other study results in the application, supporting a planned U.S. launch after clearance. INBS stock closed at $1.81, down 8.12%.
3 min readIntelligent Bio Solutions (INBS) announced it has regained compliance with Nasdaq's minimum bid price requirement as of January 7, 2026. This follows its common stock trading below $1.00 for 30 consecutive business days, leading to a deficiency notice in December 2025. The company maintained a closing bid price of at least $1.00 for 14 consecutive business days, removing the immediate delisting risk.
3 min readIntelligent Bio Solutions (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader. This collaboration aims to meet anticipated global demand, support INBS's entry into the US market in 2026, and is expected to achieve over 40% in annual production cost savings while strengthening its supply chain. The partnership leverages Syrma Johari's extensive manufacturing capacity and expertise in medical device production.
3 min readIntelligent Bio Solutions (INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech, aiming to reduce production costs by over 40% and improve gross margins by approximately 20 percentage points. This collaboration quadruples manufacturing capacity in preparation for the planned 2026 U.S. market entry of their fingerprint drug screening reader. The partnership leverages Syrma Johari's extensive global facilities and regulatory certifications to strengthen INBS's supply chain and support future growth.
4 min readIntelligent Bio Solutions Inc (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech, aiming to significantly enhance global production and improve gross margins by 20 percentage points. This collaboration is expected to achieve over 40% annual production cost savings and strengthen INBS's supply chain, supporting its planned U.S. market entry in 2026. Syrma Johari's production capacity is four times INBS's current output.
2 min readIntelligent Bio Solutions Inc. (NASDAQ:INBS) stock dropped 21.3% after announcing a $10 million private placement. The medical technology company will issue nearly 2.3 million shares and warrants to two healthcare-focused institutional investors, with the proceeds intended for working capital and general corporate purposes. This significant decline suggests investor concern over potential share dilution.
3 min readNEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Intelligent Bio Solutions Inc. ( NASDAQ:INBS ) ( "INBS" or the "Company" ) , a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital ...
3 min readNEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Intelligent Bio Solutions Inc. ( Nasdaq: INBS ) ( "INBS" or the "Company" ) , a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital ...
4 min readRecord quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion ...
2 min read
